A class of diabetes drugs (SGLT2 inhibitors) cuts hospitalizations for heart failure by a third and lowers death risk by nearly 40% — even before blood sugar improves — suggesting they protect the...

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes

Narrative Review

2025 Jul

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes

Score: 1

DOI: 10.1007/s13300-025-01743-6

Similar Assertions

People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower fasting insulin levels than those using other diabetes drugs.

77%

People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower levels of a key inflammation marker called interleukin-6 than those taking other diabetes medications.

72%

Type 2 diabetes patients taking SGLT-2 inhibitors have lower levels of uric acid in their blood than those on other diabetes medications.

72%